BIOMEA FUSION, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.57 USD | +7.73% |
|
+7.43% | -20.32% |
| 04-03 | North American Morning Briefing : Powell Awaited -2- | DJ |
| 04-02 | Biomea Fusion Shares Decline Following JPMorgan Downgrade | MT |
| Sales 2024 * | - | Sales 2025 * | 2.5M 200M | Capitalization | 417M 33.25B |
|---|---|---|---|---|---|
| Net income 2024 * | -157M -12.53B | Net income 2025 * | -179M -14.28B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 167 x |
| P/E ratio 2024 * |
-2.83
x | P/E ratio 2025 * |
-2.9
x | Employees | 103 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.9% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +7.73% | ||
| 1 week | +7.43% | ||
| Current month | +7.73% | ||
| 1 month | -24.38% | ||
| 3 months | -40.67% | ||
| 6 months | +10.72% | ||
| Current year | -20.32% |
1 week
10.39
12.08
1 month
10.2214.43
Current year
10.2220.21
1 year
8.1343.69
3 years
2.8443.69
5 years
2.8443.69
10 years
2.8443.69
| Managers | Title | Age | Since |
|---|---|---|---|
Tom Butler
CEO | Chief Executive Officer | 43 | 31/07/17 |
Ramses Erdtmann
FOU | Founder | 60 | 31/07/17 |
Franco Valle
DFI | Director of Finance/CFO | 43 | 25/07/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ramses Erdtmann
FOU | Founder | 60 | 31/07/17 |
Sumita Ray
BRD | Director/Board Member | 50 | 15/06/21 |
Bihua Chen
BRD | Director/Board Member | 55 | 30/11/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +1.32% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 11.57 | +7.73% | 1,116,873 |
| 30/04/24 | 10.74 | -0.09% | 589,833 |
| 29/04/24 | 10.75 | -0.28% | 512,171 |
| 26/04/24 | 10.78 | +2.96% | 583,288 |
| 25/04/24 | 10.47 | -2.79% | 501,987 |
Delayed Quote Nasdaq, May 01, 2024 at 09:00 pm
More quotes
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
11.57
USD
Average target price
49.38
USD
Spread / Average Target
+326.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.32% | 417M | |
| +0.67% | 42.4B | |
| +44.30% | 40.04B | |
| -6.20% | 28.31B | |
| +6.55% | 24.94B | |
| -21.66% | 18.96B | |
| +29.96% | 12.3B | |
| -1.57% | 11.95B | |
| +16.03% | 11.32B | |
| -4.80% | 11.55B |
- Stock Market
- Equities
- BMEA Stock
